NeuroSense Therapeutics (NRSN) News Today $1.09 -0.01 (-0.91%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$1.08 -0.01 (-0.46%) As of 02/21/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period NeuroSense Therapeutics Reports Positive Phase 2b Study Results for ALS TreatmentFebruary 19 at 10:06 AM | tipranks.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Elevance Health (ELV) and Genmab (GMAB)February 4, 2025 | markets.businessinsider.comNeuroSense regains Nasdaq complianceJanuary 8, 2025 | markets.businessinsider.comNeuroSense Regains Nasdaq Compliance, Strengthens Position for ALS TreatmentJanuary 6, 2025 | tipranks.comNeuroSense Regains Compliance with Nasdaq's Minimum Equity RequirementJanuary 6, 2025 | prnewswire.comNeuroSense files to sell 5.28M ordinary shares for holdersDecember 27, 2024 | markets.businessinsider.comNeuroSense Therapeutics files to sell 5.28M ordinary shares for holdersDecember 27, 2024 | msn.comNeuroSense enters binding term sheet to advance PrimeC for ALSDecember 24, 2024 | markets.businessinsider.comNeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALSDecember 23, 2024 | prnewswire.comNeuroSense Advances ALS Treatment with PrimeC, Boosts Financial PositionDecember 19, 2024 | markets.businessinsider.comNeuroSense Provides Business Update and Third Quarter 2024 Financial ResultsDecember 18, 2024 | prnewswire.comNeuroSense Therapeutics Regains Nasdaq ComplianceDecember 17, 2024 | tipranks.comMaxim Group Downgrades NeuroSense Therapeutics (NRSN)December 17, 2024 | msn.comNeuroSense cut to Hold at Maxim following PrimeC FDA feedbackDecember 17, 2024 | markets.businessinsider.comNeuroSense downgraded to Hold from Buy at MaximDecember 17, 2024 | markets.businessinsider.comNeuroSense Receives FDA Approval for Phase 3 Study of ALS TreatmentDecember 12, 2024 | markets.businessinsider.comNeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeCDecember 11, 2024 | prnewswire.comNeuroSense’s PrimeC Shows Promise in ALS TreatmentDecember 6, 2024 | markets.businessinsider.comNeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALSDecember 4, 2024 | prnewswire.comNeuroSense Therapeutics Announces Securities Purchase AgreementDecember 2, 2024 | markets.businessinsider.comNeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market PriceDecember 2, 2024 | prnewswire.comNeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MNDNovember 21, 2024 | prnewswire.comNeuroSense Therapeutics Secures Continued Nasdaq ListingNovember 13, 2024 | markets.businessinsider.comNeuroSense Completes Key ALS Trial PhaseNovember 1, 2024 | markets.businessinsider.comNeurosense Therapeutics Secures $30 Million Equity DealNovember 1, 2024 | markets.businessinsider.comNeuroSense Therapeutics Advances ALS Drug Development PlansOctober 29, 2024 | markets.businessinsider.comEXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application SubmissionOctober 28, 2024 | msn.comNeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA SubmissionOctober 28, 2024 | prnewswire.comNeuroSense’s PrimeC shows microRNA improvement in ALSOctober 25, 2024 | markets.businessinsider.comNeuroSense’s PrimeC Shows Potential in ALS TreatmentOctober 25, 2024 | markets.businessinsider.comNew Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS PatientsOctober 24, 2024 | prnewswire.comNeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further UpdatesOctober 15, 2024 | prnewswire.comNeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in CanadaOctober 9, 2024 | prnewswire.comNeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual MeetingOctober 7, 2024 | prnewswire.comNeuroSense Therapeutics Granted Patent for ALS Treatment FormulationSeptember 24, 2024 | marketwatch.comNeuroSense Reports Patent Grant For PrimeC Formulation - Quick FactsSeptember 24, 2024 | markets.businessinsider.comNeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer'sSeptember 24, 2024 | prnewswire.comNeuroSense Regains Compliance with NASDAQ Minimum Bid Price RuleSeptember 24, 2024 | prnewswire.comNeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price NotificationAugust 30, 2024 | prnewswire.comNeuroSense Therapeutics (NASDAQ:NRSN) Stock Quotes, Forecast and News SummaryAugust 29, 2024 | benzinga.comNeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market PriceAugust 7, 2024 | prnewswire.comNeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical TrialAugust 1, 2024 | prnewswire.comNeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease ProgressionJuly 9, 2024 | prnewswire.comNeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying DrugJuly 1, 2024 | prnewswire.comNRSN Stock Earnings: NeuroSense Therapeutics Misses EPS for Q1 2024June 24, 2024 | investorplace.comNeuroSense Management Provides Corporate Update and First Quarter 2024 Financial ResultsJune 24, 2024 | prnewswire.comNeuroSense Receives Delisting Notice from Nasdaq and Intends to AppealJune 21, 2024 | prnewswire.comEvaxion Biotech GAAP EPS of $0.03 beats by $0.53, revenue of $0.05MMay 29, 2024 | msn.comBuy Rating on Neurosense Therapeutics Backed by Promising ALS Treatment ResultsMay 25, 2024 | markets.businessinsider.comNeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development SummitMay 20, 2024 | prnewswire.com Get NeuroSense Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address NRSN Media Mentions By Week NRSN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NRSN News Sentiment▼1.620.60▲Average Medical News Sentiment NRSN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NRSN Articles This Week▼11▲NRSN Articles Average Week Get NeuroSense Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CTMX News Today CNTX News Today QNCX News Today KRON News Today UNCY News Today ONCY News Today IOBT News Today OPTN News Today RVPH News Today OTLK News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NRSN) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NRSN Stock Alerts